Results 31 to 40 of about 9,247 (168)
Despite recent progress in multiple myeloma (MM) treatments, most patients will relapse and require additional treatment. Intravenous daratumumab, a human IgGκ monoclonal antibody targeting CD38, has shown good efficacy in the treatment of MM.
Gang An +15 more
doaj +1 more source
In multiple myeloma (MM), the anti-CD38 monoclonal antibody Daratumumab has become essential in the therapeutic arsenal, although very few predictive factors of response to Daratumumab have been identified in clinical studies.
Djamila Chemlal +15 more
doaj +1 more source
Melphalan flufenamide (melflufen), a first-in-class alkylating peptide-drug conjugate, plus dexamethasone was approved in Europe for use in patients with triple-class refractory relapsed/refractory multiple myeloma (RRMM) with ≥3 prior lines of therapy ...
Luděk Pour +15 more
doaj +1 more source
Regulatory harmonization: Evolution, globalization and future directions
Regulatory harmonization has become an increasingly important and accepted approach to streamline regulatory review processes and expedite access to safe, effective and high‐quality medicines globally. This review explores the evolution and current status of regulatory harmonization, convergence and reliance initiatives.
Orin Chisholm +2 more
wiley +1 more source
Affinity Peptides With pH Sensitivity for the Enrichment of CD38+ Cells
ABSTRACT The selective enrichment of cell populations based on surface markers is critical for the advancement of gene and cell therapies. Current antibody‐based cell isolation methods, such as fluorescence‐ and magnetic‐activated cell sorting (FACS and MACS), offer high specificity but are limited by scalability, cost, and potential adverse effects on
Gabrielle Rusch +7 more
wiley +1 more source
Epigenetic regulation of CD38/CD48 by KDM6A mediates NK cell response in multiple myeloma
Anti-CD38 monoclonal antibodies like Daratumumab (Dara) are effective in multiple myeloma (MM); however, drug resistance ultimately occurs and the mechanisms behind this are poorly understood.
Jiye Liu +21 more
doaj +1 more source
This Account showcases a modular, multi‐arm linker platform that decouples payload loading from antibody conjugation. By leveraging a computationally designed ACPGHA zinc‐binding motif, we demonstrate the construction of homogeneous antibody‐drug conjugates and theranostic antibody‐radionuclide conjugates with high payload loading. The multi‐arm linker
Cédric Grauffel +2 more
wiley +1 more source
The real-world outcomes of multiple myeloma patients treated with daratumumab.
Most patients cannot be included in randomized clinical trials. We report real-world outcomes of all Danish patients with multiple myeloma (MM) treated with daratumumab-based regimens until 1 January 2019.MethodsInformation of 635 patients treated with ...
Agoston Gyula Szabo +17 more
doaj +1 more source
ABSTRACT Multiple myeloma (MM) is a malignant plasma cell disorder that primarily presents with CRAB symptoms (calcium elevation, renal failure, anemia, and bone abnormalities). In rare cases, MM manifests with systemic complications like skin ulcers, which present management challenges. Here, we report a 78‐year‐old Japanese man with MM and refractory
Naoko Hattori +5 more
wiley +1 more source
Multiomics Insights Into AL Amyloidosis
ABSTRACT Light chain amyloidosis is a systemic or localized protein conformational disorder triggered by misfolded immunoglobulin light chains, leading to amyloid fibril deposition. The disease is characterized by multiorgan involvement and delayed diagnosis, contributing to poor prognosis and high mortality rates.
Zixuan Zhang +6 more
wiley +1 more source

